Syncor’s Profit for 3rd Quarter Up 65%

Syncor International Corp., a provider of specialty pharmaceuticals, said its fiscal third-quarter profit jumped 65% from a year earlier on a 39% increase in sales.

In the quarter ended Feb. 29, Syncor’s net income rose to $1.35 million from $817,000 a year earlier, and its sales climbed to $53.3 million from $38.3 million. Syncor said the introduction of three new cardiology-related products contributed to the gains.

For the first nine months of its fiscal year, Syncor’s profit rose 54%, to $4.48 million from $2.91 million, and its nine-month sales increased 35%, to $151.2 million from $111.7 million.